$1.61
Alterity Therapeutics is a biotechnology business based in the US. Alterity Therapeutics shares (ATHE) are listed on the NASDAQ and all prices are listed in US Dollars. Alterity Therapeutics employs 11 staff and has a trailing 12-month revenue of around $3.4 million.
Our top picks for where to buy Alterity Therapeutics stock
How to buy Alterity Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ATHE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Alterity Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Alterity Therapeutics stock price (NASDAQ: ATHE)
Use our graph to track the performance of ATHE stocks over time.Alterity Therapeutics shares at a glance
Latest market close | $1.60 |
---|---|
52-week range | $1.55 - $5.41 |
50-day moving average | $1.92 |
200-day moving average | $2.12 |
Wall St. target price | $7.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.67 |
Is it a good time to buy Alterity Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alterity Therapeutics price performance over time
Historical closes compared with the close of $1.6 from 2024-07-25
1 week (2024-07-19) | -11.06% |
---|---|
1 month (2024-06-27) | -10.11% |
3 months (2024-04-26) | -36.25% |
6 months (2024-01-26) | -19.60% |
1 year (2023-07-27) | -43.66% |
---|---|
2 years (2022-07-26) | 166.67% |
3 years (2021-07-27) | 22.14% |
5 years (2019-07-26) | 43.42% |
Alterity Therapeutics financials
Revenue TTM | $3.4 million |
---|---|
Gross profit TTM | $3.6 million |
Return on assets TTM | -28.94% |
Return on equity TTM | -53.72% |
Profit margin | 0% |
Book value | $0.01 |
Market Capitalization | $17.6 million |
TTM: trailing 12 months
Alterity Therapeutics share dividends
We're not expecting Alterity Therapeutics to pay a dividend over the next 12 months.
Have Alterity Therapeutics's shares ever split?
Alterity Therapeutics's shares were split on a 1:10 basis on 8 January 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alterity Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Alterity Therapeutics shares which in turn could have impacted Alterity Therapeutics's share price.
Alterity Therapeutics share price volatility
Over the last 12 months, Alterity Therapeutics's shares have ranged in value from as little as $1.55 up to $5.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alterity Therapeutics's is 0.713. This would suggest that Alterity Therapeutics's shares are less volatile than average (for this exchange).
Alterity Therapeutics overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. .
Frequently asked questions
nullWhat percentage of Alterity Therapeutics is owned by institutions?
Currently 1.073% of Alterity Therapeutics shares are held by institutions. How many people work for Alterity Therapeutics?
Latest data suggests 11 work at Alterity Therapeutics. When does the fiscal year end for Alterity Therapeutics?
Alterity Therapeutics's fiscal year ends in June. Where is Alterity Therapeutics based?
Alterity Therapeutics's address is: 350 Collins Street, Melbourne, VIC, Australia, 3000 What is Alterity Therapeutics's ISIN number?
Alterity Therapeutics's international securities identification number is: US02155X1063 What is Alterity Therapeutics's CUSIP number?
Alterity Therapeutics's Committee on Uniform Securities Identification Procedures number is: 02155X106
More guides on Finder
-
Options trading strategies for beginners
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
Ask a question